Lipocine director granted options for 2,000 shares

Lipocine director Michael Grissinger received a grant of 2,000 stock options on August 3, 2026, each for Lipocine common stock at an exercise price of $2.11 per share and expiring on August 3, 2036.

Rhea-AI Filing Summary

Lipocine director Michael Grissinger received a grant of 2,000 stock options on August 3, 2026, each for Lipocine common stock at an exercise price of $2.11 per share and expiring on August 3, 2036. The options are subject to vesting: one-third of the shares vest on the one-year anniversary of August 3, 2027, and the remaining two-thirds vest monthly on a prorata basis over the following two years. The transaction was not reported as made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Grant/Award: 2,000 shares

Grant/Award 1 txn

Insider Grissinger Michael

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	2,000	$2.11	$4K

Holdings After Transaction: Stock Option (Right to Buy) — 2,000 contracts (Direct)

Footnotes (1)

1. F1. Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of August 3, 2027, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years.

Key Figures

Options granted: 2,000 shares Exercise price: $2.11 per share Expiration date: 2036-08-03 +3 more

6 metrics

Options granted 2,000 shares Stock options for Lipocine common stock granted to director Michael Grissinger

Exercise price $2.11 per share Exercise price for the 2,000 granted stock options

Expiration date 2036-08-03 Expiration of the reported stock option grant

Post-transaction derivative holdings 2,000 options Total stock options held after this reported grant

Initial vesting tranche 1/3 of shares Vests on the one-year anniversary of August 3, 2027

Remaining vesting period 2 years Remaining two-thirds of the award vest monthly over the following two years

Key Terms

Stock Option (Right to Buy), vesting, Common Stock

3 terms

Stock Option (Right to Buy) financial

"Security title reported as Stock Option (Right to Buy) for common stock"

vesting financial

"Subject to vesting whereby 1/3 of the shares will vest on the one year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"Underlying security title identified as Common Stock for the option award"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lipocine (LPCN) director Michael Grissinger report on this Form 4?

Michael Grissinger reported receiving a grant of 2,000 stock options for Lipocine common stock. The options have a $2.11 per share exercise price, expire on August 3, 2036, and vest over three years beginning one year after August 3, 2027.

How many Lipocine (LPCN) stock options were granted and at what exercise price?

The filing reports a grant of 2,000 stock options to director Michael Grissinger. Each option is exercisable for Lipocine common stock at an exercise price of $2.11 per share, as specified in the transaction details.

What is the vesting schedule for Michael Grissinger's LPCN stock options?

The options are subject to vesting, with one-third of the shares vesting on the one-year anniversary of August 3, 2027. The remaining two-thirds of the award vest monthly on a prorata basis over the following two years.

When do the Lipocine (LPCN) options awarded to Grissinger expire?

The granted stock options expire on August 3, 2036. After that expiration date, any unexercised options from this 2,000-share award will no longer be exercisable for Lipocine common stock.

Were Michael Grissinger’s Lipocine (LPCN) option grants made under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not checked, indicating the transaction was not reported as made under a Rule 10b5-1 trading plan. The award appears as a standard director option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 04:12 PM Accepted by SEC EDGAR 08/07/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grissinger Michael

(Last) (First) (Middle)

675 ARAPEEN DRIVE

SUITE 202

(Street)

SALT LAKE CITY UTAH 84108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lipocine Inc. [ LPCN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.11	08/03/2026		A		2,000		08/03/2027(1)	08/03/2036	Common Stock	2,000	$2.11	2,000	D

Explanation of Responses:

1. Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of August 3, 2027, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years.

	/s/ Michael Grissinger	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)